Charles M. Rudin
查尔斯·鲁丁
MD, PhD
Chief, Thoracic Oncology Service; Laurance S. Rockefeller Chair胸部肿瘤科主任；洛克菲勒讲席教授
👥Biography 个人简介
Dr. Charles Rudin is a world authority on SCLC biology at MSK. He defined the ASCL1, NEUROD1, and YAP1 molecular subtypes of SCLC, fundamentally reshaping understanding of disease heterogeneity and enabling subtype-specific therapeutic strategies including DLL3-targeted approaches.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
SCLC Molecular Subtype Classification
Defined transcription-factor-based SCLC subtypes (ASCL1, NEUROD1, YAP1, POU2F3), providing a framework for precision medicine in SCLC and guiding DLL3 and other targeted therapy development.
Representative Works 代表性著作
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Nature Reviews Cancer (2019)
Seminal classification of SCLC into four molecular subtypes based on lineage transcription factors, reshaping biology-driven treatment strategies.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 查尔斯·鲁丁 的研究动态
Follow Charles M. Rudin's research updates
留下邮箱，当我们发布与 Charles M. Rudin（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment